Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Roden

Showing results (101-110 of 1,010) with videos related to

Pageof 101
Sort By:
Circulation|March 29, 2001
Preprescription genotyping: not yet ready for prime time, but getting thereD M Roden, N J Brown
Clinical Pharmacokinetics|March 1, 1988
Clinical pharmacokinetics of encainideD M Roden, R L Woosley
Trends in Cardiovascular Medicine|January 20, 2011
Toward a molecular view of cardiac arrhythmogenesisD M Roden, M M Tamkun
Clinical Pharmacology and Therapeutics|February 18, 2011
Pharmacogenomics at the tipping point: challenges and opportunitiesD M Roden, R F Tyndale
The American Surgeon|November 1, 1993
Penetrating injuries to the neck: a safe, selective approach to managementD M Roden, R A Pomerantz
Nature Reviews. Drug Discovery|November 3, 2005
Drug therapy for atrial fibrillation: where do we go from here?Richard L Page, Dan M Roden
Pharmacology & Therapeutics|January 1, 1983
Class I antiarrhythmic agents: quinidine, procainamide and N-acetylprocainamide, disopyramideD M Roden, R L Woosley
The American Journal of Cardiology|September 22, 1983
Importance of metabolites in antiarrhythmic therapyR L Woosley, D M Roden
Circulation|June 30, 2010
Responding to the clopidogrel warning by the US food and drug administration: real life is complicatedDan M Roden, Alan R Shuldiner
The New England Journal of Medicine|July 3, 1986
Drug therapy. TocainideD M Roden, R L Woosley
Pageof 101

Showing results (101-110 of 1,010) with videos related to

Sort By:
Pageof 101
Circulation|March 29, 2001
Preprescription genotyping: not yet ready for prime time, but getting thereD M Roden, N J Brown
Clinical Pharmacokinetics|March 1, 1988
Clinical pharmacokinetics of encainideD M Roden, R L Woosley
Trends in Cardiovascular Medicine|January 20, 2011
Toward a molecular view of cardiac arrhythmogenesisD M Roden, M M Tamkun
Clinical Pharmacology and Therapeutics|February 18, 2011
Pharmacogenomics at the tipping point: challenges and opportunitiesD M Roden, R F Tyndale
The American Surgeon|November 1, 1993
Penetrating injuries to the neck: a safe, selective approach to managementD M Roden, R A Pomerantz
Nature Reviews. Drug Discovery|November 3, 2005
Drug therapy for atrial fibrillation: where do we go from here?Richard L Page, Dan M Roden
Pharmacology & Therapeutics|January 1, 1983
Class I antiarrhythmic agents: quinidine, procainamide and N-acetylprocainamide, disopyramideD M Roden, R L Woosley
The American Journal of Cardiology|September 22, 1983
Importance of metabolites in antiarrhythmic therapyR L Woosley, D M Roden
Circulation|June 30, 2010
Responding to the clopidogrel warning by the US food and drug administration: real life is complicatedDan M Roden, Alan R Shuldiner
The New England Journal of Medicine|July 3, 1986
Drug therapy. TocainideD M Roden, R L Woosley
Pageof 101